Customize
Quick Links
Specialties

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps
for Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies focuses on areas of clinical challenge faced by practicing oncologists, along with emerging therapeutic approaches being developed to tackle these challenges.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Agios.

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies

Release Date: March 31, 2017
Expiration Date: March 31, 2018
Media: Internet - based

 

Activity Overview

This activity focuses on emerging therapies for acute myeloid leukemia (AML). It features a series of short video interviews with leading experts in the field. The content and interviews are based on presentations given in January 2017 at New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies, a series of live symposia that were held adjunct to the Highlights of ASH® in North America conferences in Seattle. In their interviews, Program Chair Eytan Stein, MD, and the faculty, Daniel J. DeAngelo, MD, PhD; and Harry Erba, MD, PhD, review and share perspectives on current standards of care, the clinical implication of new data, and advances of novel therapeutic strategies.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Agios.

CME/CE Activity Table of Contents

  • The Biology of AML and Its Therapeutic Implications
    Daniel DeAngelo, MD, PhD
  • Assessing Potential Therapeutic Targets in AML
    Harry Erba, MD, PhD
  • Current and Emerging Roles for Multikinase Inhibitors in Patients With Activating FLT3 Mutations
    Daniel DeAngelo, MD, PhD
  • IDH Inhibitors: A Look at Evolving Data Sets and Ongoing Clinical Trials
    Eytan Stein, MD
  • Methods to Optimize Outcomes in Older Adults With AML
    Harry Erba, MD, PhD
  • A Look at the Near Future: Rationale Drug Combinations With Targeted Agents in AML
    Eytan Stein, MD
  • Posttest

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is intended for medical oncologists, hematologists, nurses, physician assistants, fellows and other healthcare professionals interested in emerging data and advances in treatment of AML.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Determine contemporary strategies for the management of AML and clinically unmet needs in the field
  • Discuss activating mutations identified in AML that provide the rationale for the development of targeted mechanistic approaches
  • Explain recent clinical trial results concerning novel targeted strategies to manage AML and next steps in the field with single agent and combination trials
  • Place recent clinical trial findings on targeted strategies in the context of evolving treatment paradigms and how targeted approaches may be used to optimize outcomes in AML

Faculty, Staff, and Planners' Disclosures

Faculty

Daniel J. DeAngelo, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Physician, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosure: Consultant: Amgen, Bristol-Myers Squibb, Ariad, Incyte, Pfizer, Novartis, Celgene

Harry Erba, MD, PhD
Professor of Medicine
Director of the UAB Hematologic Malignancy Program
Associate Director for Clinical Research
The University of Alabama Comprehensive Cancer Center
Birmingham, Alabama

Disclosure: Grant/Research Support: Agios, Amgen, Astellas, Celator, Immunogen, Janssen, Juno, Seattle Genetics, Takeda/Millennium; Consultant: Novartis, Incyte, Celgene, Daiichi Sankyo, Pfizer, Amgen, Sunesis, Janssen, Seattle Genetics, Jazz, Immunogen, Ono; Speaker’s Bureau: Novartis, Incyte, Celgene

Eytan Stein, MD
Assistant Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

Disclosure: Advisory Board Member – Celgene Pharmaceuticals

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.




PER Pulse™ Recap (1 of 3)

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in January 2017 in Seattle, Washington. In this online activity, expert faculty discuss standards of care and emerging therapies for acute myeloid leukemia (AML). It features commentary on:

  • The biology of AML and its therapeutic implications by Daniel DeAngelo, MD, PhD
  • Potential therapeutic targets by Harry Erba, MD, PhD
  • Multikinase inhibition for FLT3-mutated AML by Daniel DeAngelo, MD, PhD
  • Evolving data sets and clinical trials of IDH inhibitors by Eytan Stein, MD
  • Optimization of outcomes for older adults by Harry Erba, MD, PhD
  • Rational drug combinations in AML by Eytan Stein, MD

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr DeAngelo’s answers to questions about multikinase inhibition for FLT3-mutated AML.

Mutations in the FMS-like tyrosine kinase receptor gene (FLT3) are the most common genetic lesions found in AML. Patients with AML who harbor activating mutation(s) of FLT3 have a higher risk of relapse and poorer overall survival compared with patients with FLT3 wild-type AML. Current therapeutic goals for these patients include achieving first complete remission with induction chemotherapy followed by stem cell transplantation. Improved treatment options and outcomes for this group of patients represents a significant unmet need. Toward that end, researchers have been actively seeking to understand and characterize the biology of FLT3-positive AML and to develop therapeutics targeted to this subtype. During his interviews, Dr DeAngelo reviews and discusses ongoing studies of broad- and narrow-spectrum multikinase inhibitors in clinical trial for FLT3-mutated AML, including midostaurin, lestaurtinib, sorafenib, quizartinib, crenolanib, and gilteritinib.




PER Pulse™ Recap (2 of 3)

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in January 2017 in Seattle, Washington. In this online activity, expert faculty discuss standards of care and emerging therapies for acute myeloid leukemia (AML). It features commentary on:

  • The biology of AML and its therapeutic implications by Daniel DeAngelo, MD, PhD
  • Potential therapeutic targets by Harry Erba, MD, PhD
  • Multikinase inhibition for FLT3-mutated AML by Daniel DeAngelo, MD, PhD
  • Evolving data sets and clinical trials of IDH inhibitors by Eytan Stein, MD
  • Optimization of outcomes for older adults by Harry Erba, MD, PhD
  • Rational drug combinations in AML by Eytan Stein, MD

This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr Stein’s answers to questions about the development of IDH inhibitors for AML.

Mutations of the isocitrate dehydrogenase 1 or 2 (IDH1/2) genes are found in approximately 20% of adult patients with AML. Several IDH1/2 inhibitors are being investigated in clinical trial for AML. Of these, the IDH2 inhibitor enasidenib is furthest along. In phase II study, a 37% overall response rate was reported among patients with relapsed/refractory (R/R) AML who received enasidenib. Antitumor activity has also been demonstrated in early-phase studies of the IDH1 inhibitors AG-129 and IDH305. The Food and Drug Administration granted priority review to a new drug application for enasidenib as a treatment for IDH2-mutated, R/R AML. Dr Stein reviews data on these agents and discusses future directions with IDH inhibitors in AML, including their use in combination with standards of care and other targeted therapies.




PER Pulse™ Recap (3 of 3)

Community Practice Connections™: Highlights of ASH®: New Frontiers in the Management of AML Treatment: The Emerging Role of Targeted Therapies is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in January 2017 in Seattle, Washington. In this online activity, expert faculty discuss standards of care and emerging therapies for acute myeloid leukemia (AML). It features commentary on:

  • The biology of AML and its therapeutic implications by Daniel DeAngelo, MD, PhD
  • Potential therapeutic targets by Harry Erba, MD, PhD
  • Multikinase inhibition for FLT3-mutated AML by Daniel DeAngelo, MD, PhD
  • Evolving data sets and clinical trials of IDH inhibitors by Eytan Stein, MD
  • Optimization of outcomes for older adults by Harry Erba, MD, PhD
  • Rational drug combinations in AML by Eytan Stein, MD

This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr Erba’s answers to questions about optimizing outcomes for older patients with AML.

Most patients diagnosed with AML are aged ≥ 65 years. Significant improvements in outcomes of younger adults with AML have been realized over the past few decades. Unfortunately, outcomes for older adults have remained poor due to a variety of patient- and disease-related factors. The biology of AML in older adults differs from that of younger patients, featuring karyotypes and mutational profiles that are more adverse and complex. Dr Erba discusses standards of care for older adults with AML, as well as emerging data that should be considered during decision making. Additionally, he reviews novel chemotherapeutic and targeted therapies being investigated for this population, including vosaroxin, CPX-351, vadastuximab (SGN-33A), and venetoclax.








Become a Member

Forgot Password?
Filter By